Abstract:8533 Background: Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residue disease in lung cancer after definitive treatment. Herein, we investigated the value of ctDNA in prognosing risk of relapse and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer (NSCLC) patients. Methods: Forty-one surgical NSCLC patients were enrolled. Tumor tissues were collected at surgery and subjected to targeted NGS of 1021 cancer-related genes. The serial peripheral blood samples were collected at postoperative one month and then at every third or sixth month and subjected to ultra-deep targeted NGS covering 338 genes. Results: From 41 eligible patients including 18 patients with stage I disease, 2 with stage II and 21 with stage III, 41 tumor tissues and 137 plasma samples were enrolled and successfully tested. In tissue samples, 323 somatic variations were identified, with a median of 8 (range, 1-21) gene variations detected in each patient. TP53 was the most common mutation (63.41%), followed by EGFR (58.53%), LRP1B (17.07%) and KRAS (14.63%). The first-postoperative ctDNA positive was found in 13 of 41 patients (31.71%), 9 stage III, 2 stage II and 2 stage I. During a median 9.47 months follow-up, 38.46% (5/13) patients with detectable ctDNA in the first postoperative blood sample experienced recurrence, while 3.57% (1/28) patients with undetectable ctDNA ultimately recurred. The DFS can be stratified by the first-postoperative ctDNA status, with ctDNA-positive groups having significantly reduced DFS (p < 0.05). We detected ctDNA in at least one time point after surgery in 17 patients (41.46%), 5 of them (29.41%) experienced recurrence. Twenty-four patients without ctDNA detection during postoperative surveillance, one (4.17%) of them ultimately recurred. Serial ctDNA detection revealed disease recurrence ahead of radiologic imaging by a median of 5.25 months (range, 0.98-14.19). Among the 41 patients, 6 patients had surgery alone, 35 patients received adjuvant therapy. For these 35 patients, ctDNA analysis can stratify patients before and after adjuvant therapy. Recurrence ratio was 33.33% (4/12) in patients with detectable and 4.34% (1/23) in patients with undetectable ctDNA before adjuvant therapy. For ctDNA analysis after adjuvant therapy, no patients (11/11) with negative ctDNA had disease-recurrence while 33.33% (1/3) patients with positive ctDNA experienced recurrence. All four patients with clearance ctDNA by adjuvant therapy remained disease free. Conclusions: For NSCLC patients, postoperative ctDNA is a prognostic marker, which reveals disease recurrence ahead of radiographic examination. Importantly, ctDNA-detecting may facilitate personalized adjuvant therapy, and applying adjuvant therapy to the patients with detectable ctDNA could bring clinical benefits for them.

Clinical significance of postoperative folate receptor‐positive circulating tumor cells (FR + CTCs) for long‐term prognosis in patients with invasive adenocarcinoma (IAC) of the lung

Preoperative levels of folate receptor-positive circulating tumor cells in different subtypes of early-stage lung adenocarcinoma: Predictive value for determining extent of surgical resection

Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients

Folate Receptor-Positive Circulating Tumor Cells Predict Survival and Recurrence Patterns in Patients Undergoing Resection for Pancreatic Cancer

Prognostic Value of Circulating Tumor Cells and Circulating Tumor Microemboli in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non–small cell lung cancers.

Clinical Significance of a Circulating Tumor Cell-Based Classifier in Stage IB Lung Adenocarcinoma

Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients

Clinical, Imaging, and Pathological-Molecular Characteristics Associated with Stage IA Invasive Lung Adenocarcinoma Recurrence After Sub-lobar Resection

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC

Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection

Survival Prediction and Adjuvant Chemotherapy Based on Tumor Marker for Stage IB Lung Adenocarcinoma.

Association of circulating tumor cell-white blood cell clusters with survival outcomes in patients with colorectal cancer after curative intent surgery

Prognostic Value of Tumor Immune Microenvironment Factors in Patients with Stage I Lung Adenocarcinoma.

Risk Factors of Postoperative Recurrence and Potential Candidate of Adjuvant Radiotherapy in Lung Adenosquamous Carcinoma

Patterns and Risks of Postoperative Recurrence in Completely Resected EGFR-mutant Non-Small Cell Lung Cancer: Prognostic Significance of Routine Immunohistochemical Markers

Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.

The Clinical Values of Circulating Tumor Cells and T Lymphocyte Subsets in Predicting a Prognosis of Lung Cancer

Prognostic Significance and Survival Benefits of Postoperative Adjuvant Chemotherapy in Patients with Stage IA Lung Adenocarcinoma with Non-Predominant Micropapillary Components

Preoperative CA19-9 Levels Predict Disease-Free Survival and Overall Survival in Pancreatic Adenocarcinoma Patients after Resection.